We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ADM:NYSEArcher-Daniels-Midland Company Analysis

Data as of 2026-03-10 - not real-time

$68.20

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Archer‑Daniels‑Midland is trading at $68.2, well above its DCF fair value of $43.6, implying a ~11% downside from the model. The stock sits above its 20‑day, 50‑day and 200‑day SMAs (68.21 > 65.72 > 59.64), a classic bullish alignment, yet the MACD shows a bearish crossover (histogram –0.24) and volume is on a decreasing trend, suggesting short‑term pressure. RSI at 54 is neutral, while 30‑day volatility of 21% and a low beta of 0.43 point to modest market sensitivity but heightened price swings. Fundamentals are mixed: revenue fell 13.7% year‑over‑year, margins are thin (gross 6.3%, operating 1.8%, net 1.3%), and debt‑to‑equity is high at 42, but the dividend yield is attractive at 3.06% with a payout ratio near 92%. Recent earnings beat EPS expectations ($0.87 vs $0.83) but missed revenue forecasts, prompting analysts to lift price targets modestly to $63–$68 and noting insider buying of $486k at $64.90. Overall, the stock appears overvalued relative to its cash‑flow fundamentals, with limited growth upside and dividend sustainability concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA alignment but bearish MACD divergence
  • Recent EPS beat offset by revenue miss
  • High dividend yield but near‑limit payout ratio

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Significant revenue decline and thin profitability margins
  • Elevated leverage (debt‑to‑equity 42) and overvaluation vs DCF
  • Decreasing volume trend indicating waning investor interest

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Defensive consumer‑staples exposure with steady demand for ag commodities
  • Attractive dividend yield tempered by sustainability concerns
  • Strategic ESG initiatives (e.g., carbon capture) that could enhance future stability

Key Metrics & Analysis

Financial Health

Revenue Growth-13.70%
Profit Margin1.34%
P/E Ratio30.6
ROE4.72%
ROA1.71%
Debt/Equity42.38
P/B Ratio1.4
Op. Cash Flow$5.5B
Free Cash Flow$2.1B

Technical Analysis

TrendBullish
RSI54.3
Support$65.50
Resistance$70.48
MA 20$68.21
MA 50$65.72
MA 200$59.64
MACDBearish
VolumeDecreasing
Fear & Greed Index77.38

Valuation

Fair Value$43.60
Target Price$60.73
Upside/Downside-10.96%
GradeOvervalued
TypeValue
Dividend Yield3.06%

Risk Assessment

Beta0.43
Volatility21.09%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.